Weak Cell Therapy Product Sales Due to the Small Number of Patients Eligible for Advanced Medicine
First written in FY2017-Q1. 2 of 5 entries say "Restated". Latest entry: 2026-05-13.
Medinet moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Materialised".
- 2026-05-13MaterialisedEarnings
「The number of immune-cell processing procedures declined at some client medical institutions due to a decrease in overseas patients from countries subject to travel restrictions to Japan.」
The decline in overseas patients reduced the number of immune-cell processing procedures, demonstrating the risk associated with sluggish patient numbers. - FY2022-Q3RestatedAnnual report
「The prolonged COVID-19 pandemic continued to depress the number of inbound patients at medical institutions with which the company does business, while the recovery in the number of domestic patients was also limited,」
The sluggish number of inbound patients and limited recovery in the number of domestic patients have continued. - FY2020-Q1RestatedAnnual report
「Although the number of patients, mainly inbound patients, is increasing, the recovery in patient numbers is expected to remain limited owing to changes in the market environment for cancer immunotherapy and other factors.」
The company continued to explain that although the number of patients at contracted medical institutions increased, mainly among inbound patients, the recovery remained limited because of changes in the market environment. - FY2017WorsenedAnnual report
「In the cell therapy products business, the company is exploring the potential of cell therapy products through R&D, including the discovery of candidates leading to cell therapy products, technology improvements and the acquisition of intellectual property rights, together with the results of R&D conducted by the group and ongoing joint research with university hospitals and other institutions. Revenue was ¥1.481 million, down ¥31.123 million year on year, a 95.5% decline.」
Revenue from the cell therapy products business fell 95.5% year on year for the full year, and remained sluggish. - FY2017-Q1First statedAnnual report
「Revenue from the cell therapy products business declined 99.6% year on year because there were few patients eligible for advanced medicine.」
The Company states that the 99.6% year-on-year decline in cell therapy product revenue was caused by the small number of patients eligible for advanced medicine.